A serotonin receptor subtype expressed in cardiovascular tissue, the gastrointestinal system, and the trigeminal system. Distinct from the 5-HT2A receptor that mediates psilocybin's psychedelic and antidepressant effects. 5-HT2B and 5-HT2C agonism may mediate psilocybin's preventive effects on cluster headaches and migraines at sub-psychedelic doses — explaining why therapeutic headache benefits occur independently of the intensity of the psychedelic experience. Chronic 5-HT2B agonism at high doses raises theoretical cardiovascular concerns, though this is not a documented issue at therapeutic psilocybin doses.
The 5-HT2B receptor is a serotonin receptor subtype expressed in cardiovascular tissue, the gastrointestinal system, and the trigeminal system. Distinct from the 5-HT2A receptor that mediates psilocybin's psychedelic and antidepressant effects. 5-HT2B and 5-HT2C agonism may mediate psilocybin's preventive effects on cluster headaches and migraines at sub-psychedelic doses — explaining why therapeutic headache benefits occur independently of the intensity of the psychedelic experience. Chronic 5-HT2B agonism at high doses raises theoretical cardiovascular concerns, though this is not a documented issue at therapeutic psilocybin doses.
See: Cluster Headaches (/conditions/cluster-headaches).
Understanding 5-HT2B helps explain why psilocybin can relieve cluster headaches at sub-psychedelic doses and why headache benefits do not depend on having a strong psychedelic experience.